|
rs2279744
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, the present meta-analysis indicates that MDM2 rs1690916 and rs2279744 cannot be considered as genetic risk factors for OS susceptibility in the different populations.
|
27438225 |
2016 |
|
rs4150441
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis did not reveal significant associations between ERCC2 rs13181/rs1799793 or ERCC3 rs4150441/ rs4150506 gene polymorphisms and the development of osteosarcoma in codominant, dominant, and recessive models.
|
27051024 |
2016 |
|
rs1128503
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We conclude that ABCC3 rs4148416 polymorphism was significantly associated with poor osteosarcoma response and ABCB1 rs1128503 polymorphism was significantly associated with good osteosarcoma response in Caucasian population rather than Asian population.
|
26107220 |
2015 |
|
rs17655
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We conducted a perspective study to investigate the role of ERCC1 (rs11615), ERCC2 (rs13181 and rs1799793), ERCC4 (rs1800067), and ERCC5 (rs17655) in NER pathway in the prognosis of osteosarcoma patients.
|
26436406 |
2015 |
|
rs1800470
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The morbidity and metastasis of osteosarcoma are relevant to TGF-β1 gene 29 T > C single nucleotide polymorphism.
|
25663491 |
2015 |
|
rs2298881
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, our findings suggest that ERCC1 rs11615 and ERCC1 rs2298881 genetic polymorphisms are significantly associated with poor response to chemotherapy and unfavourable survival of osteosarcoma.
|
26339355 |
2015 |
|
rs2298881
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In summary, our results suggested that the ERCC1 rs11615 and rs2298881 polymorphisms play important roles in the response to chemotherapy mediated by the DNA repair pathway and in the clinical outcome of osteosarcoma.
|
26345951 |
2015 |
|
rs4148416
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We conclude that ABCC3 rs4148416 polymorphism was significantly associated with poor osteosarcoma response and ABCB1 rs1128503 polymorphism was significantly associated with good osteosarcoma response in Caucasian population rather than Asian population.
|
26107220 |
2015 |
|
rs454006
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results suggested that the T/C variant of rs454006 located in the intron 3 region of PRKCG gene was significantly associated with an increased risk of osteosarcoma (CC vs. TT, OR = 1.91; 95 % CI 1.29-2.85; P = 0.001; CC vs. TT+TC, OR = 2.14, 95 % CI = 1.48-3.09, P = 0.001; C vs. T, OR = 1.32, 95 % CI = 1.08-1.62, P = 0.008).
|
25663494 |
2015 |
|
rs7034162
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We identified an SNP, rs7034162, in NFIB significantly associated with metastasis in European osteosarcoma cases, as well as in cases of African and Brazilian ancestry (meta-analysis of all cases: P = 1.2 × 10(-9); OR, 2.43; 95% confidence interval, 1.83-3.24).
|
26084801 |
2015 |
|
rs820196
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We selected rs820196 in the RECQL5 gene and genotyped 185 patients with osteosarcoma and 201 age- and gender-matched non-cancer controls.
|
25867335 |
2015 |
|
rs1690916
|
|
|
0.020 |
GeneticVariation |
BEFREE |
MDM2 rs1690916 polymorphism was also associated with a risk of osteosarcoma (OR = 0.60, 95 % CI 0.46-0.77, P < 0.001).
|
24122202 |
2014 |
|
rs1800541
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs1800541-rs2070699 haplotypes TG and GT were respectively associated with increased (P = 0.012; adjusted OR, 1.82; 95% CI, 1.10-5.65) and reduced (P = 0.009; adjusted OR, 0.25; 95% CI, 0.14-0.84) risk of chemoresistant OS.
|
24123836 |
2014 |
|
rs1906953
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Further analysis showed the association between rs1906953 and OS was independent of gender and age.
|
24984297 |
2014 |
|
rs2070699
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs1800541-rs2070699 haplotypes TG and GT were respectively associated with increased (P = 0.012; adjusted OR, 1.82; 95% CI, 1.10-5.65) and reduced (P = 0.009; adjusted OR, 0.25; 95% CI, 0.14-0.84) risk of chemoresistant OS.
|
24123836 |
2014 |
|
rs2279744
|
|
|
0.020 |
GeneticVariation |
BEFREE |
However, MDM2 rs2279744 polymorphism was not associated with the overall survival of patients with osteosarcoma (codominant model, HR = 1.01, 95 % CI 0.53-1.91, P = 0.98; recessive model, HR = 1.07, 95 % CI 0.54-2.11, P = 0.85; dominant model, HR = 1.04, 95 % CI 0.65-1.66, P = 0.87).
|
24122202 |
2014 |
|
rs4148416
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, variants of ABCB1 rs128503, ABCC3 rs4148416, and GSTP1 rs1695 are associated with response to chemotherapy and PFS and OS of osteosarcoma patients; these gene polymorphisms could help in the design of individualized therapy.
|
24996541 |
2014 |
|
rs454006
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs454006 polymorphism of the PRKCG gene correlated to osteosarcoma susceptibility and might increase the risk of osteosarcoma.
|
25252845 |
2014 |
|
rs820196
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We also found that the C allele of rs820196 (OR = 1.492, 95% CI 1.138 ∼ 1.951; P = 0.004) and A allele of rs4789223 (OR = 1.767, 95% CI: 1.354 ∼ 2.301; P < 0.001) were common in the osteosarcoma patients than those in the control subjects, respectively.
|
24287950 |
2014 |
|
rs1047768
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our findings showed polymorphisms in ERCC5 rs1047768 and MMS19L rs29001322 to be associated with clinical outcome of osteosarcoma patients undergoing chemotherapy.
|
23679317 |
2013 |
|
rs1800541
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The mRNA and the secreted protein levels of ET-1 in primary OS cell cultures (POCCs) established from surgically resected primary OS in the rs1800541 TT homozygotes were higher than those from the TG heterozygotes (P<0.05), who in turn showed higher ET-1 mRNA and secreted ET-1 levels than the GG homozygotes (P<0.05).
|
24069190 |
2013 |
|
rs2070699
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The G allele at rs1800541 was found associated with reduced risk of pulmonary metastatic OS after adjustment for body mass index, systolic blood pressure, diastolic blood pressure and the plasma ET-1 level (P=10(-4); adjusted OR, 0.55; 95% CI, 0.42-0.70), while the G allele at rs2070699 was not significantly associated with the risk of pulmonary metastatic OS (P=0.15; adjusted OR, 1.15; 95% CI, 0.87-1.50).
|
24069190 |
2013 |
|
rs17655
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Excision repair cross-complementing (ERCC) group 2 (XPD; rs13181 and rs1799793), group 5 (XPG; rs17655) and group 1 (XPA; rs3212986 and rs11615) polymorphisms were analyzed in a group of 130 homogenously treated patients with high-grade osteosarcoma, for association with event-free survival (EFS), using the Kaplan-Meier plots and log-rank test.
|
21826087 |
2012 |
|
rs28934576
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Some of the genetic changes identified were in tumor suppressor genes previously identified as altered in osteosarcoma: p53 (arginine→histidine at codon 273 [R273H], R→cysteine at codon 723 [R273C], and tyrosine→C at codon 163 [Y163C]) and retinoblastoma 1 (RB1) (glutamic acid→* at codon 137 [E137*]).
|
22006429 |
2012 |
|
rs231775
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The current study evaluated the association of four CTLA-4 gene mutations, -1661A/G (rs4553808), -318C/T (rs5742909), +49G/A (rs231775), and CT60A/G (rs3087243), with osteosarcoma in the Chinese population.
|
21612409 |
2011 |